Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer

14 Mar 2019

Abstract excerpt

Urinary bladder cancer is a common malignancy, being characterized by substantial patient mortality and management cost. Its high somatic-mutation frequency and molecular heterogeneity usually renders tumors refractory to the applied regimens. Hitherto, methotrexate-vinblastine-adriamycin-cisplatin and gemcitabine-cisplatin represent the backbone of systemic chemotherapy. However, despite the initial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Genomics, phytochemicals, and oxidative stress
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30875794
DOI: 10.3390/ijms20061291

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder CancerPMID 30875794Read ↗

[Epigenetics in urothelial cancer: Pathogenesis, improving diagnostics and developing novel treatment options].Semantic proximity Read ↗

Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidenceSemantic proximity Read ↗

Limited efficacy of specific HDAC6 inhibition in urothelial cancer cellsSemantic proximity Read ↗

Histone-Deacetylase Inhibitors for the Treatment of CancerSemantic proximity Read ↗

HDAC4 overexpression predicts aggressive phenotypes and poor outcomes in urothelial carcinoma.Semantic proximity Read ↗

SIRT4 is an independent prognostic factor in bladder cancer and inhibits bladder cancer growth by suppressing autophagySemantic proximity Read ↗

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and ChemopreventionSemantic proximity Read ↗

SIRT1 and gynecological malignancies (Review)Semantic proximity Read ↗

Role of histone deacetylase inhibitors in non-neoplastic diseasesSemantic proximity Read ↗

New Approaches to Targeting Epigenetic Regulation in Bladder CancerSemantic proximity Read ↗

SWI/SNF Alterations Define a Chromatin-Dependent Subtype of Urothelial CarcinomaSemantic proximity Read ↗

Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model SystemsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.